PhI­Ib win puts Nim­bus one step clos­er to chal­leng­ing Bris­tol My­ers in TYK2

Bris­tol My­ers Squibb might be the first to clinch an FDA ap­proval for a TYK2 in­hibitor, but Nim­bus Ther­a­peu­tics is out to prove that it has the best drug in the class. The biotech says it now has pos­i­tive mid-stage da­ta to back up those claims — al­though it’s sav­ing the hard num­bers for now.

Topline re­sults from a Phase IIb study in­volv­ing 259 pa­tients with mod­er­ate-to-se­vere plaque pso­ri­a­sis showed that Nim­bus’ drug, NDI-034858, hit the pri­ma­ry end­point of help­ing more pa­tients achieve PASI-75 than place­bo at 12 weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER